Skeletal muscle degeneration and loss of function is at the basis of Duchenne muscular dystrophy (DMD) pathology. Our work focuses on understanding differences between normal, wild-type mouse muscle and the same muscle in the mdx mouse, a spontaneous mutant mouse line that is an animal model for DMD. The differences we study affect muscle microtubule organization. Normal mouse muscles have a periodic grid-like microtubule network, whereas mdx mouse muscles have a disordered, denser network. We still understand little of muscle microtubule organization despite the essential and diverse roles played by microtubules in all mammalian cells and their dramatic reorganization at every stage of muscle development. Furthermore, physiological and pharmacological research on mdx muscle, complemented by RNAseq of human DMD samples, has led others to claim that microtubules underlie mdx and DMD pathology. Previously we showed that microtubules are dynamic, constantly growing, and that their path is aligned with that of the protein dystrophin, which is lacking in mdx and DMD and directly interacts with microtubules. However, a dystrophin construct lacking the microtubule binding site was able to rescue microtubules in a transgenic mdx mouse line, casting doubt on the overall role of dystrophin in microtubule organization. We decided to search for other molecules potentially responsible for the differences in microtubule organization. Microtubules are assembled from linear chains of alpha- and beta-tubulin dimers. Both alpha- and beta-tubulins have 8 to 10 isotypes, allowing for structural and possibly functional diversity. We noticed that the RNA for one of the beta-tubulin isotypes, tubb6 (beta 6 class V), is most increased in DMD compared to normal muscle; furthermore, overexpression of this ubiquitous, minor beta-tubulin isoform modifies the microtubule network of proliferating cells (Bhattacharya et al. 2011, Mol Biol Cell, 22, 1025-34). Tubb6 thus appeared worth investigating. Last year we reported that tubb6 is remarkably increased in mdx compared to wild-type mice (from 3- to 20- fold depending on specific muscle). Additionally, overexpression of a GFP construct of tubb6 causes distortion and density increase of the microtubule network in WT mouse muscle. In comparison, overexpression of the same GFP construct of another beta tubulin, TUBB5, caused no modification of the microtubule network. When tubb6 was decreased or suppressed in mdx muscle by shRNA treatment, the fibers expressing the shRNA --but not a non-specific shRNA or an RNA against TUBB5-- showed a nearly normal microtubule network. Thus, manipulating the level of tubb6 allows us to modify the organization of muscle microtubules, regardless of the presence or absence of dystrophin, suggesting that tubb6 plays a role in muscle microtubule organization and in the microtubule alterations of mdx. But why would tubb6 be increased in mdx and DMD, if it is toxic to muscle? We found that tubb6 is incrreased in regenerating fibers. Its increase in mdx muscle is proportional to the degree of regeneration.The change in microtubule organization observed in mdx muscle fibers is therefore not a simple direct consequence of the lack of dystrophin, but is linked to muscle regeneration. This work has been published recently (Randazzo et al., 2019). Some of our past work showed that in skeletal muscle, dynamic microtubules are nucleated on static Golgi elements. It is therefore possible that the microtubule disorder characteristic of mdx muscle fibers results from mispositioning of the Golgi elements. We have therefore investigated Golgi complex organizaton in live muscle fibers expressing fluorescently tagged microtubule markers. We have concluded that Golgi elements are anchored by an association with ER exit sites that is maintained in mdx muscle and thus does not require dystrophin. In contrast the positioning of the Golgi-ER exit site assemblies is perturbed in mdx muscle and thus may be linked to dystrophin. This work has been accepted for publication in Frontiers in Cell and Developmental Biology.

Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
2019
Total Cost
Indirect Cost
Name
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Department
Type
DUNS #
City
State
Country
Zip Code
Iglesias-Bartolome, Ramiro; Uchiyama, Akihiko; Molinolo, Alfredo A et al. (2018) Transcriptional signature primes human oral mucosa for rapid wound healing. Sci Transl Med 10:
Duverger, Olivier; Carlson, Jenna C; Karacz, Chelsea M et al. (2018) Genetic variants in pachyonychia congenita-associated keratins increase susceptibility to tooth decay. PLoS Genet 14:e1007168
Tsai, Pei-Fang; Dell'Orso, Stefania; Rodriguez, Joseph et al. (2018) A Muscle-Specific Enhancer RNA Mediates Cohesin Recruitment and Regulates Transcription In trans. Mol Cell 71:129-141.e8
Lim, Jeong-A; Sun, Baodong; Puertollano, Rosa et al. (2018) Therapeutic Benefit of Autophagy Modulation in Pompe Disease. Mol Ther 26:1783-1796
Madsen, Agnete B; Knudsen, Jonas R; Henriquez-Olguin, Carlos et al. (2018) ?-Actin shows limited mobility and is required only for supraphysiological insulin-stimulated glucose transport in young adult soleus muscle. Am J Physiol Endocrinol Metab 315:E110-E125
Ferdinand, John R; Richard, Arianne C; Meylan, Fran├žoise et al. (2018) Cleavage of TL1A Differentially Regulates Its Effects on Innate and Adaptive Immune Cells. J Immunol 200:1360-1369
Duverger, Olivier; Cross, Michael A; Smith, Frances J D et al. (2018) Enamel anomalies in a pachyonychia congenita patient with a mutation in KRT16. J Invest Dermatol :
Milgroom, Andrew; Ralston, Evelyn (2016) Clearing skeletal muscle with CLARITY for light microscopy imaging. Cell Biol Int 40:478-83
Suzuki, Ryo; Leach, Sarah; Liu, Wenhua et al. (2014) Molecular editing of cellular responses by the high-affinity receptor for IgE. Science 343:1021-5
Feeney, Erin J; Austin, Stephanie; Chien, Yin-Hsiu et al. (2014) The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathol Commun 2:2

Showing the most recent 10 out of 19 publications